RecruitingNCT07517250

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel

Sponsor

Novartis Pharmaceuticals

Enrollment

160 participants

Start Date

Mar 15, 2026

Study Type

OBSERVATIONAL

Conditions

Still Disease Adult Onset Still Disease Familial Mediterranean Fever Systemic Juvenile Idiopathic Arthritis

Summary

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Eligibility

Min Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with adult onset still disease, familial mediterranean fever, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.